Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
复制标题
DOI：
--
复制
发表时间：
2006-11
影响因子：
2
通讯作者：
N. Iizuka;I. Sakaida;T. Moribe;N. Fujita;T. Miura;M. Stark;S. Tamatsukuri;H. Ishitsuka;K. Uchida;S. Terai;Kazuhiko Sakamoto;T. Tamesa;M. Oka
中科院分区：
文献类型：
--
作者：
N. Iizuka;I. Sakaida;T. Moribe;N. Fujita;T. Miura;M. Stark;S. Tamatsukuri;H. Ishitsuka;K. Uchida;S. Terai;Kazuhiko Sakamoto;T. Tamesa;M. Oka
背景技术患有几种癌症之一的患者血液中循环游离DNA的含量增加。材料和方法采用谷胱甘肽 S-转移酶 pi (GSTP1) 基因实时 PCR 检测方法来测量 52 名丙型肝炎病毒 (HCV) 相关肝细胞癌 (HCC) 患者血清中的游离 DNA 水平，其中包括 30 名无已知 HCC 的 HCV 携带者和 16 名 HCV 阴性非癌症患者（对照）。结果 HCC 患者血清中的游离 DNA 水平显着高于 HCV 携带者或对照受试者的血清。无细胞 DNA 水平与肿瘤分化程度和大小相关，但与患者年龄、性别、TNM 分期或甲胎蛋白 (AFP) 或缺乏维生素 K 诱导的蛋白质 (PIVKA-II) 水平无关。在最佳截断值为 73.0 ng/ml 时，无细胞 DNA 检测在区分 HCC 和 HCV 携带者方面的灵敏度为 69.2%，特异性为 93.3%，受试者工作特征曲线下面积为 0.90（95% CI，0.83-0.96）。游离DNA的辨别力优于AFP或PIVKA-II。结论 我们的结果表明，HCV 相关 HCC 患者血清中循环游离 DNA 水平显着升高，表明循环游离 DNA 可能是 HCV 相关 HCC 特异性的良好生物标志物。
BACKGROUND Circulating cell-free DNA is present in increased amounts in the blood of patients with one of several forms of cancer. MATERIALS AND METHODS A real-time PCR assay with glutathione S-transferase pi (GSTP1) gene was used to measure cell-free DNA levels in the sera of 52 patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV), which included 30 HCV carriers without known HCC and 16 HCV-negative non-cancer patients (controls). RESULTS Cell-free DNA levels were significantly higher in the sera from HCC patients than in the sera from HCV carriers or the control subjects. Cell-free DNA levels were associated with the degree of tumor differentiation and size but not patient age, gender, TNM stage or levels of alpha-fetoprotein (AFP) or protein induced by vitamin K absence (PIVKA-II). The cell-free DNA assay had a sensitivity of 69.2% and a specificity of 93.3% in discriminating HCC and HCV carriers at the optimal cut-off value of 73.0 ng/ml, with an area of 0.90 (95% CI, 0.83-0.96) under the receiver operating characteristic curve. The discriminative power of cell-free DNA was superior to that of AFP or PIVKA-II. CONCLUSION Our results showed that levels of circulating cell-free DNA are significantly increased in sera of patients with HCV-associated HCC, suggesting that circulating cell-free DNA may be a good biomarker specific for HCV-associated HCC.